We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+12.46%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$670M
AUM Growth
+$172M
Cap. Flow
+$37.5M
Cap. Flow %
5.59%
Top 10 Hldgs %
63.01%
Holding
164
New
62
Increased
39
Reduced
20
Closed
34

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.49M
2
CNVS icon
Cineverse
CNVS
+$6.05M
3
SHIP icon
Seanergy Maritime Holdings
SHIP
+$5.68M
4
RMTI icon
Rockwell Medical
RMTI
+$5.66M
5
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$5.55M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.6M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.7M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$2.89M
4
PLLL
Piedmont Lithium Limited American Depositary Receipts
PLLL
+$2.88M
5
ALNA
Allena Pharmaceuticals
ALNA
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 12.1%
2 Technology 0.73%
3 Industrials 0.54%
4 Communication Services 0.41%
5 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRDF icon
26
PUT
Cardiff Oncology
CRDF
$63.6M
$5.52M 0.82%
+3,887
New +$25.7K
JJT
27
CALL
DELISTED
iPath Series B Bloomberg Tin Subindex Total ReturnSM ETN
JJT
$4.92M 0.73%
+1,976
New +$91.3K
IMMU
28
DELISTED
Immunomedics Inc
IMMU
$4.25M 0.63%
+50,000
New +$2.53M
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.45B
$4.12M 0.62%
+99,921
New +$4.31M
AVEO
30
PUT
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$4.04M 0.6%
6,801
-506
-7% -$2.5K
RMTI icon
31
Rockwell Medical
RMTI
$27.6M
$3.85M 0.57%
+32,686
New +$5.66M
SPI
32
DELISTED
SPI Energy Co., Ltd. Ordinary Shares
SPI
$3.06M 0.46%
+425,762
New +$912K
ITCI
33
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.95M 0.44%
+115,000
New +$2.62M
AZN icon
34
CALL
AstraZeneca
AZN
$267B
$2.85M 0.43%
+261
New +$29K
INO icon
35
PUT
Inovio Pharmaceuticals
INO
$84.7M
$2.81M 0.42%
202
+22
+12% +$4.59K
CNVS icon
36
Cineverse
CNVS
$56.4M
$2.75M 0.41%
+243,797
New +$6.05M
TRIL
37
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.64M 0.39%
1,860
-415
-18% -$4.14K
CKPT
38
DELISTED
Checkpoint Therapeutics
CKPT
$2.5M 0.37%
+93,124
New +$2.24M
VXX icon
39
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$159M
$2.49M 0.37%
+1,563
New +$2.78M
COCP icon
40
Cocrystal Pharma
COCP
$12.9M
$2.48M 0.37%
+222,274
New +$4.06M
SHIP icon
41
Seanergy Maritime Holdings
SHIP
$348M
$2.44M 0.36%
+534,928
New +$5.68M
XWEL icon
42
XWELL
XWEL
$8.87M
$2.35M 0.35%
+59,562
New +$3.48M
NMRD
43
DELISTED
Nemaura Medical, Inc. Common Stock
NMRD
$2.18M 0.33%
+613,765
New +$3.58M
NVCN
44
DELISTED
Neovasc Inc.
NVCN
$2.16M 0.32%
40,376
+27,335
+210% +$1.58M
PULM icon
45
Pulmatrix
PULM
$6.14M
$2.07M 0.31%
87,033
+86,436
+14,478% +$2.2M
CLDX icon
46
CALL
Celldex Therapeutics
CLDX
$2.79B
$2.06M 0.31%
1,392
+610
+78% +$7.15K
PRFX icon
47
PRF Technologies Ltd
PRFX
$3.25M
$2.05M 0.31%
+371
New +$2.56M
IONS icon
48
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$2.03M 0.3%
428
+304
+245% +$16.9K
BLU
49
DELISTED
BELLUS Health Inc.
BLU
$2M 0.3%
+880,400
New +$2.5M
DXR icon
50
Daxor
DXR
$62.2M
$1.93M 0.29%
+122,406
New +$2.07M
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sabby Management held 164 positions worth $670M, up 34% from $498M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $37.5M of net new capital in Q3 2020, opening 62 new positions and adding to 39 existing holdings. Its largest new stake was Cineverse: 243,797 shares worth $2.75M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 11% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Biogen, an estimated $16.6M trimmed.

  • Sabby Management's largest Q3 2020 buy was Cineverse: 243,797 shares worth $2.75M.
  • Sabby Management added most to AstraZeneca in Q3 2020, an estimated $6.49M increase.
  • Sabby Management's biggest Q3 2020 reduction was Biogen, cutting an estimated $16.6M.
  • Sabby Management fully exited Xeris Biopharma Holdings in Q3 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 63% of its $670M portfolio in Q3 2020.
  • Sabby Management opened 62 new positions and closed 34 in Q3 2020.
  • Sabby Management's portfolio value rose 34% quarter-over-quarter to $670M.

Based on Sabby Management's 13F filing for Q3 2020, filed 16 Nov 2020.